The future of protein-based vaccines: Why mRNA is transforming the landscape, but all platforms remain essential

The rapid evolution of vaccine technology, driven by the unprecedented success of mRNA platforms during the COVID-19 pandemic, has fundamentally shifted our approach to protein-based vaccines. mRNA vaccines offer a transformative combination of speed, scalability, and adaptability, making them the platform of choice for rapid pandemic response and for addressing emerging infectious diseases. Read more … mRNA vaccines: speed, scale, and flexibility mRNA vaccine technology stands out for its unparalleled pre-clinical development and production speed. Once a pathogen’s genetic sequence is known and the product is licensed, mRNA vaccines can be manufactured within 4–8 weeks—a fraction of the time required for traditional platforms. The production process is cell-free, standardized, and highly scalable: a single 5-liter bioreactor can yield millions of doses, and the same facility can pivot rapidly to produce vaccines against new strains or entirely different pathogens simply by changing the RNA sequence. These features translate to lower capital costs, higher...